Gen-Wealth Partners’s Editas Medicine EDIT Stock Holding History

Gen-Wealth Partners’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$131	Hold	53	–	–	﹤0.01%	717
2025 Q4	$109	Hold	53	–	–	﹤0.01%	684
2025 Q3	$184	Hold	53	–	–	﹤0.01%	674
2025 Q2	$117	Hold	53	–	–	﹤0.01%	637
2025 Q1	$61	Hold	53	–	–	﹤0.01%	615
2024 Q4	$67	Hold	53	–	–	﹤0.01%	644
2024 Q3	$160	Hold	53	–	–	﹤0.01%	651
2024 Q2	$248	Hold	53	–	–	﹤0.01%	630
2024 Q1	$393	Buy	+53	New	+$440	﹤0.01%	609

Other funds holding EDIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Gen-Wealth Partners's EDIT Position: Q1 2026 in Review

Gen-Wealth Partners held its Editas Medicine (EDIT) position steady in Q1 2026 at 53 shares worth $131. The position accounts for ﹤0.01% of the portfolio, ranked #717.

Gen-Wealth Partners first reported a position in EDIT in Q1 2024 and has held it in 9 quarters since. The position peaked at $393 in Q1 2024. 207 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

Gen-Wealth Partners held 53 shares of Editas Medicine worth $131 as of Q1 2026.
Gen-Wealth Partners left its Editas Medicine share count unchanged in Q1 2026.
Editas Medicine made up ﹤0.01% of Gen-Wealth Partners's portfolio in Q1 2026, its #717 holding.
Gen-Wealth Partners first reported a position in Editas Medicine in Q1 2024 and has held it in 9 quarters since.
Gen-Wealth Partners's Editas Medicine position peaked at $393 in Q1 2024.
207 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on Gen-Wealth Partners's 13F filing for Q1 2026, filed 8 May 2026.